ENTITY
WuXi AppTec

WuXi AppTec (2359 HK)

563
Analysis
Health Care • China
WuXi AppTec is a global contract research, development, and manufacturing organization (CRDMO) for the pharmaceutical and life sciences industries. It provides integrated, end-to-end services including chemistry drug CRDMO, biology discovery, preclinical testing, and clinical research services for various therapeutic modalities. The company was founded in 2000 and is headquartered in Shanghai, China.
more
bullish•WuXi AppTec
•30 Apr 2026 07:46•Broker

WuXi AppTec (603259 CH) - 1Q26 results: small molecule D&M fuelling overall growth

Revenue grew by 28.8% YoY to RMB12.4bn with continuing operations revenue increasing by 39.4% YoY, while adj. non-IFRS attributable net profit...

Logo
109 Views
Share
bullish•WuXi AppTec
•28 Apr 2026 09:27•Broker

Quam Morning Note (28 Apr) - Wuxi AppTec

Wuxi Apptec reported a revenue increase of 28.8% y/y in 1Q26. Wuxi AppTec (2359 HK, NR) announced that it achieved total revenue of RMB12.44bn in...

Logo
115 Views
Share
bullish•WuXi AppTec
•26 Mar 2026 07:22•Broker

WuXi AppTec (603259 CH) - Strong CDMO Demand to Fuel 2026 Growth

WuXi AppTec reported impressive financial results for 2025, with revenue growing by 15.8% YoY (including 21.4% YoY growth for continuing...

Logo
142 Views
Share
bullish•WuXi AppTec
•24 Mar 2026 09:24•Broker

Quam Morning Note (24 Mar) - Wuxi Apptec

Hong Kong market commentary A-share market commentary Wuxi Apptec reported a revenue increase of 15.8% y/y in 2025

Logo
138 Views
Share
bullish•WuXi AppTec
•28 Oct 2025 20:38•Broker

WuXi AppTec (603259 CH) - Rising Demand for Small Molecule D&M Business

WuXi AppTec reported strong 3Q25 results, with revenue increasing by 15.3% YoY (including 19.7% YoY growth for continuing operations) and adj. non...

Logo
223 Views
Share
x